- Before
- “I need to know which of 2,846 contracts can bite us, and by when” — and the first pass would take outside counsel weeks.
- Now
- Opens each contract already read, with the clause, the outcome and the clock; confirms or changes it and signs the notices.
One acquisition, from data room to signed letters
Northwind Bio acquired Kelvara Therapeutics by reverse triangular merger, closing Sep 14, 2026. It is Oct 7, Day 23. Here is what happens next, screen by screen, in the working solution.
- 01Day 23 · morning
The whole inherited estate on one screen
Lena Ortiz · Integration counselEvery Kelvara contract that needs action is a tile, grouped by contract family, sized by its value a year and coloured by what the takeover triggers; each family's no-action contracts form one grey block. The chips across the top count it: 74 consent required, 9 exclusivity conflicts, 212 notices, 41 for a lawyer's read and 2,510 needing no action. The largest red tile in licences and collaborations is Aldermoor University Research Foundation, at $26M a year.
“All 2,846 contracts read Sep 15–18 · $852M a year in the estate · $172M sits behind 74 consents, 15 still open.”
- 02Sep 15–18
3,412 files become 336 contracts that need action
The agentsThe Data room intake agent classified every file, kept the executed version and grouped amendments and work orders under their agreement: 3,412 files, 2,846 contracts. The Clause finder pulled each relevant clause with its page and section, and the Trigger analyst applied the deal structure and governing law. Each of the 336 contracts that need action shows the clause that triggered it, how sure the read is, the clock and the letter.
“No action: the reverse triangular merger leaves Kelvara as the party, so plain anti-assignment clauses are not triggered.”
- 03One click on the tile
Aldermoor can end the licence behind KLV-210
Lena Ortiz · Integration counselThe Exclusive License Agreement opens beside the agents' reading. §14.2 bars transfer “by merger, by operation of law, by Change of Control or otherwise” without the Foundation's consent, so it bites even though Kelvara is still the same company. Northwind acquired 100% of Kelvara's voting securities, a Change of Control under §14.3(a). Without consent the Foundation may terminate within 60 days of closing — by Nov 13, 2026, 37 days from today.
“Consent needed · 97% · Proposed by the Trigger analyst — confirm or change.”
- 04The consent runway
Every consent request against its termination window
Lena Ortiz · Integration counselBelow the estate, each consent request runs from closing to its counterparty's deadline, with today's line through them all: drafted, signed and sent, reminders and replies. Thornbury University Research Foundation has been waiting 11 days and was reminded Oct 3; Halden Rise University Research Foundation granted consent Oct 7. Nine requests, Aldermoor's among them, are still to draft.
“27 granted · 32 waiting · 6 with the signatory · 9 to draft.”
- 05One step
“Draft the 9 requests”
Letter writerLena drafts all nine at once. The Letter writer fills each request from its approved template, quotes the triggering clause and routes it to Omar Haddad for e-signature; the runway updates in place. The button now reads “Every request drafted”, with 15 requests with the signatory and none left to draft.
The Letter writer never changes legal wording, never sends unsigned, and sends nothing before closing.
- 066 seconds
A consent request that quotes its clause
Letter writerAldermoor's request is drafted from “Consent request — licence v3”, addressed to the Office of Technology Licensing from the notices clause, with §14.2 quoted and cited. The guard rails ran first: closing has happened, the signatory has authority, no legal wording changed. It goes to Omar Haddad, who signs consent requests.
“Drafted in 6 seconds from Consent request — licence v3. Every quoted clause is cited.”
- 077 days left
Solvane's covenant now reaches Veltrimab
Commitments checkerSolvane Pharma AG's §7.1 bars Kelvara “and its Affiliates” from any IL-23 pathway product for inflammatory bowel disease, and Northwind became an Affiliate on Sep 14. Its Veltrimab, an IL-23 p19 antibody in Phase 3 for ulcerative colitis and Crohn's disease, overlaps on mechanism, indication and territory. The §7.4 acquirer carve-out is available: Veltrimab existed at closing and nothing in the data room shows shared people or data, but it needs a written notice by Oct 14 and a firewall.
The Commitments checker never decides a conflict — Omar Haddad does.
- 08Decided
Rely on the carve-out, firewall the programme
Omar Haddad · Associate General Counsel, TransactionsOmar weighs three options: rely on the acquirer carve-out and firewall Veltrimab, ask Solvane for a waiver, or escalate to the deal team for a divest-or-terminate decision under §7.5. He records his decision with a note for the record. The acquirer-programme notice is drafted for his signature and the firewall memo goes to the programme team.
“Omar Haddad decided: Rely on the carve-out.” — recorded in the audit trail.
- 09Due Oct 14
The notices due at Day 30, in one step
Lena Ortiz · Integration counselThe Letters board runs from to draft through drafted, awaiting signature and sent to replied. The change-of-control notices due Oct 14 — Merrowfield Clinical Research's MSA §18.3 among them — need no consent, so Lena drafts them in one step from “Change-of-control notice v4”, each quoting its own notice clause and going to the address in that contract, and signs them herself.
“Draft the 119 notices due Oct 14.”
- 10Steering committee
Are we inside every window?
Dana Okafor · Integration office leadThe integration office sees the deal in one view: 2,846 contracts read in 4 days, 155 letters sent and 79 replies since Sep 14, 27 of 74 consents secured, 121 clocks open in the next 14 days and 3 of 9 conflicts decided. A family-by-outcome grid opens the contracts behind any cell, and reply rates show which families are slow to answer.